The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a study ...
This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...
Weight loss medications Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.
An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...
A large analysis of weight-loss drugs like Ozempic and Wegovy has surprised health researchers, who found links to multiple new benefits – and some new side effects.
Weight-loss jabs could reduce your risk of drug abuse, seizures and pneumonia, as well as heart attacks and strokes, ...
Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback